Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

AIM: Maintenance treatment in ulcerative colitis should be as convenient as possible, to increase the chance of compliance. MMX mesalazine is a once-daily, high-strength (1.2 g/tablet) formulation of 5-aminosalicylic acid. This study evaluated the safety and efficacy of MMX mesalazine dosed once or...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamm, M A, Lichtenstein, G R, Sandborn, W J, Schreiber, S, Lees, K, Barrett, K, Joseph, R
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2008
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564831/
https://www.ncbi.nlm.nih.gov/pubmed/18272546
http://dx.doi.org/10.1136/gut.2007.138248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564831/
https://www.ncbi.nlm.nih.gov/pubmed/18272546
http://dx.doi.org/10.1136/gut.2007.138248

Ejemplares similares